Jason Litten, MD is Chief Medical Officer at Genelux Corporation. As a biopharmaceutical executive for over 20 years in academia, large pharma, and innovative biotech companies, he has led the design, execution, and interpretation of Phase 1-4 clinical trials in liquid and solid tumors, with expertise across biologics, small molecules, and cellular therapies.
Years of joint industry-academic engineering suggest that highly engineered single agents will not be the most effective treatments for solid tumors; the solution will be combining the right drugs and administering them in the right way.